The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells

By sjmartinez • February 19, 2024

Lewis MI, Shapiro S, Oudiz RJ, Nakamura M, Geft D, Matusov Y, Hage A, Tapson VF, Henry TD, Azizad P, Saggar R, Mirocha J, Karpov OA, Van Eyk JE, Marbán E. The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells. EBioMedicine. 2024 Feb;100:104900. doi: 10.1016/j.ebiom.2023.104900. Epub 2023 Dec 12. PMID: 38092579.

Tags: Cardiology/Epi, Cedars Sinai DoM, Harbor UCLA, Progenitor cell therapy, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, Regenerative medicine, right ventricle, Short- and long-term safety, Veterans Administration

Related Posts

Brief Report: Association of HIV and HCV With Adverse Coronary Artery Phenotypes in Women: Findings From a Cross-Sectional Study

Shitole SG, Chen E, Naveed M, Xue X, Sharma A, Hanna DB, Anastos K, Kaplan RC, Levsky JM, Tien PC, Radparvar AA, Bortnick AE, Budoff[...]

A microbiome quantitative trait locus in SLC39A8 modulates disease severity in synucleinopathy-induced models of Parkinson’s disease

Yang JC, Situ J, Troutman R, Zhu R, Black M, Buri H, Gutta A, Tian F, Kang A, Aja E, Zeng A, Lai RW, Tan[...]

Latency of Hypertensive Disorders of Pregnancy and Cardiovascular Risk 2-7 Years After Delivery

Shree S, Pike M, Yee LM, Levine L, Simhan H, Silver RM, Greenland P, Saade G, Bairey Merz CN, Chung J, Cleary EM, Grobman W,[...]